Natpara Institutional Expansion Openings

Quote






  • During animal drug testing, NATPARA caused some rats to develop a bone cancer called osteosarcoma. It is not known if people who take NATPARA will have a higher chance of getting osteosarcoma. Tell your doctor right away if you have pain in any areas of your body that does not go away, or any new or unusual lumps or swelling under your skin that is tender to touch.
  • NATPARA is only available through the NATPARA Risk Evaluation and Mitigation Strategy (REMS) Program. The purpose of the NATPARA REMS Program is to inform patients about the potential risk of osteosarcoma associated with the use of NATPARA.
 
















































anonymous said:
Oh cmon, the obu is no better than a primary care job. It's a joke. These are institutional positions for an orphan drug. Stop comparing apples to oranges.
Click to expand...
Like I said, I've sold buy and bill and I've worked institutions. Your job is not that difficult. You keep telling yourself it is to justify the fact you still don't work that much and make a ridiculous amount. You're still a drug rep.
 






Talked to recruiter this morning- they are looking for the best of the best and this is an elite salesforce. The drug hasn't been at expectations and this expansion is to bring new talent in. Salary 130k+ but very competitive to get job.
 












anonymous said:
Like I said, I've sold buy and bill and I've worked institutions. Your job is not that difficult. You keep telling yourself it is to justify the fact you still don't work that much and make a ridiculous amount. You're still a drug rep.
Click to expand...

Well it sounds like you made a terrible career decision then. Electing to take a primary care position over a more specialized role. Keep looking at the postings superstar. Maybe you can get "back in".
 












yes, tons of travel, patients are starting to dry up, ship rates are brutal and you don't get paid now until it ships..which could take 3 months if it ever does. Bonus' were awesome,but mostly gone now, with the exception of a hand full of territories. Rare disease is not close to speciality sales...we're talking patient numbers of 30-50 total over multi state territories after 18 months....so hunting patients is the key.
 
























anonymous said:
Please expand. Would appreciate your insight to the differences you see. I don't think this is a sellable drug the way they think it is.
Click to expand...

There's no outcomes data. No long term renal benefits vs Ca and Vitamin D.

Added to the osteosarcoma language in the label, the drug is dead in the water.

The Marketing and Medical teams at NPS had a strategic plan in place but were shown the door once the acquisition by Shire was complete.
 












Top Bottom
Back
Quote